GLP-1 medications show promise in slowing kidney disease progression
These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...
FDA approves Ozempic to reduce risk of kidney disease progression, cardiovascular death
The Food and Drug Administration approved Ozempic to be used to lessen the risk of kidney disease from getting worse, end-stage kidney disease and cardiovascular disease-caused death for patients with ...
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...
Popular weight-loss drugs show promise in reducing kidney disease complications and mortality
A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...
clinicalpainadvisor.com15d
Ozempic Approval Expanded to Include T2D Patients With Chronic Kidney Disease
end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus (T2D) and chronic kidney disease (CKD). The approval was based on data from the randomized, double-blind, ...
Newsweek29d
Sleeping Late May Increase Risk of Death, Study Warns
Languages: English. Oversleeping may significantly increase your risk of death from chronic kidney disease. This is the conclusion of a team of researchers from Japan, who warn that sleeping ...
Hosted on MSN15d
FDA approves Ozempic to reduce risk of kidney disease progression, cardiovascular death
end-stage kidney disease and cardiovascular disease-caused death for patients with type 2 diabetes and chronic kidney disease. Read more trending news Novo Nordisk announced the approval on ...